MX2010011224A - Derivados de quinoleina como inhibidores de la cinasa axl. - Google Patents
Derivados de quinoleina como inhibidores de la cinasa axl.Info
- Publication number
- MX2010011224A MX2010011224A MX2010011224A MX2010011224A MX2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolin
- yloxy
- dimethoxy
- phenyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4539808P | 2008-04-16 | 2008-04-16 | |
| PCT/EP2009/002798 WO2009127417A1 (en) | 2008-04-16 | 2009-04-16 | Quinoline derivatives as axl kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010011224A true MX2010011224A (es) | 2011-02-25 |
Family
ID=40999731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011224A MX2010011224A (es) | 2008-04-16 | 2009-04-16 | Derivados de quinoleina como inhibidores de la cinasa axl. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9206130B2 (https=) |
| EP (1) | EP2262772B8 (https=) |
| JP (1) | JP5746015B2 (https=) |
| KR (1) | KR101325237B1 (https=) |
| CN (1) | CN102131783A (https=) |
| AU (1) | AU2009237938A1 (https=) |
| CA (1) | CA2718538A1 (https=) |
| ES (1) | ES2391373T3 (https=) |
| IL (1) | IL208103A (https=) |
| MX (1) | MX2010011224A (https=) |
| RU (1) | RU2010146474A (https=) |
| WO (1) | WO2009127417A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| ITRM20100537A1 (it) | 2010-10-12 | 2012-04-12 | Consiglio Nazionale Ricerche | Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia |
| EP2780338B1 (en) * | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| RS55728B1 (sr) | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| JP6527513B2 (ja) | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
| CA2922542A1 (en) | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| MD3436461T2 (ro) | 2016-03-28 | 2024-05-31 | Incyte Corp | Compuși pirolotriazină ca inhibitori TAM |
| CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| EP3575293B1 (en) | 2017-01-26 | 2021-03-10 | ONO Pharmaceutical Co., Ltd. | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide |
| JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含むがん治療剤 |
| MX2020002183A (es) * | 2017-08-31 | 2020-10-05 | Abbvie Inc | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos. |
| SI3687996T1 (sl) | 2017-09-27 | 2022-04-29 | Incyte Corporation | Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM |
| EP3695839A4 (en) | 2017-10-13 | 2021-07-14 | ONO Pharmaceutical Co., Ltd. | THERAPEUTIC AGENT WITH AXL INHIBITOR AS AN ACTIVE INGREDIENT FOR SOLID TUMORS |
| MD3813800T2 (ro) | 2018-06-29 | 2025-10-31 | Incyte Corp | Formulări de inhibitor al AXL/MER |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| JP2023525757A (ja) * | 2020-05-08 | 2023-06-19 | ジョージアミューン・インコーポレイテッド | Ａｋｔ３モジュレーター |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| IL144461A0 (en) | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| PT2213661E (pt) * | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| CA2619037A1 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
-
2009
- 2009-04-16 EP EP09731679A patent/EP2262772B8/en active Active
- 2009-04-16 RU RU2010146474/04A patent/RU2010146474A/ru not_active Application Discontinuation
- 2009-04-16 ES ES09731679T patent/ES2391373T3/es active Active
- 2009-04-16 MX MX2010011224A patent/MX2010011224A/es not_active Application Discontinuation
- 2009-04-16 AU AU2009237938A patent/AU2009237938A1/en not_active Abandoned
- 2009-04-16 JP JP2011504377A patent/JP5746015B2/ja active Active
- 2009-04-16 WO PCT/EP2009/002798 patent/WO2009127417A1/en not_active Ceased
- 2009-04-16 CA CA2718538A patent/CA2718538A1/en not_active Abandoned
- 2009-04-16 CN CN2009801129869A patent/CN102131783A/zh active Pending
- 2009-04-16 KR KR1020107023097A patent/KR101325237B1/ko active Active
- 2009-04-16 US US12/933,070 patent/US9206130B2/en active Active
-
2010
- 2010-09-13 IL IL208103A patent/IL208103A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL208103A (en) | 2015-08-31 |
| RU2010146474A (ru) | 2012-05-27 |
| US20110092503A1 (en) | 2011-04-21 |
| WO2009127417A1 (en) | 2009-10-22 |
| IL208103A0 (en) | 2010-12-30 |
| CA2718538A1 (en) | 2009-10-22 |
| KR101325237B1 (ko) | 2013-11-04 |
| AU2009237938A1 (en) | 2009-10-22 |
| EP2262772B1 (en) | 2012-07-18 |
| ES2391373T3 (es) | 2012-11-23 |
| CN102131783A (zh) | 2011-07-20 |
| US9206130B2 (en) | 2015-12-08 |
| EP2262772A1 (en) | 2010-12-22 |
| KR20100132038A (ko) | 2010-12-16 |
| JP2011517689A (ja) | 2011-06-16 |
| EP2262772B8 (en) | 2013-03-13 |
| JP5746015B2 (ja) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010011224A (es) | Derivados de quinoleina como inhibidores de la cinasa axl. | |
| JP6126233B2 (ja) | 新たなキノリン類の化合物及びその使用 | |
| JP5376956B2 (ja) | デュシェンヌ型筋ジストロフィーの治療 | |
| US8211901B2 (en) | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | |
| JP4521428B2 (ja) | インドールスルホンアミド化合物 | |
| EP1692124B1 (en) | Biaryl sulfonamides as mmp inhibitors | |
| EP4082538A1 (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| BRPI1011994B1 (pt) | derivados de naftaleno carboxamida como inibidores de proteína quinase e histona desacetilase, métodos de preparação e usos | |
| TW200407112A (en) | Immunity-related protein kinase inhibitors | |
| CN106478606B (zh) | N-取代吲哚类衍生物及其应用 | |
| CN106478621B (zh) | 喹啉或喹唑啉类衍生物、制备方法及其应用 | |
| CN108530426A (zh) | 含喹喔啉酮的4-苯氧基取代喹啉类化合物及其应用 | |
| WO2017045271A1 (zh) | 苯并呋喃类衍生物、其制备方法及其治疗作用 | |
| CN105461687A (zh) | 含二氢哒嗪酮的喹啉类化合物及其用途 | |
| Sun et al. | Novel piperazine-1, 2, 3-triazole leads for the potential treatment of pancreatic cancer | |
| CN117343046A (zh) | 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用 | |
| HK1156952A (en) | Quinoline derivatives as axl kinase inhibitors | |
| Long et al. | Design and Synthesis of Novel β-catenin/BCL9 Protein–Protein Interaction Small Molecule Inhibitors for the Treatment of Colorectal Cancer | |
| CN110407769B (zh) | 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途 | |
| CN104086530A (zh) | 4-取代喹啉类化合物及其应用 | |
| Zhang et al. | Zhijian Li2, 4, Huiran Qiu1, 4, Wenxia Lu1, 4, Namin Duan2, 4, Shule Fan1, Rui Zhou2, Xiangzhi Li1 | |
| CN120289287A (zh) | 一类化合物及其应用 | |
| HK40074114A (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| HK40074114B (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| CN118852135A (zh) | N-酰基磺酰胺类化合物及其制备方法、药物组合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |